1 Min Read
Sept 25 (Reuters) -
* Melinta Therapeutics presenting detailed analyses from Baxdela Phase 3 ABSSSI trials and in vitro performance against isolates of resistant CABP and other infections Source text for Eikon: Further company coverage: [ ]
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.